| Therapeutic Advances in Medical Oncology | 卷:14 |
| Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50% | |
| Meta-analysis | |
| Yingxin Xu1  Florence R. Wilson2  Patricia Guyot3  Chieh-I Chen1  Sam Keeping2  Gerasimos Konidaris4  Keith Chan2  Andreas Kuznik1  Kokuvi Atsou3  Emily Glowienka5  Jean-Francois Pouliot1  Giuseppe Gullo1  Petra Rietschel1  | |
| [1] Sanofi, Reading, UK | |
| [2] Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA | |
| [3] Precision HEOR, Boston, MA, USA | |
| [4] Sanofi, Chilly-Mazarin, France | |
| [5] Precision HEOR, Vancouver, BC, Canada | |
| 关键词: cemiplimab; cemiplimab monotherapy; IO monotherapy; network meta-analysis; non-small-cell lung cancer; PD-L1 expression; systematic literature review; | |
| DOI : 10.1177/17588359221105024 | |
| received in 2021-11-12, accepted in 2022-05-16, 发布年份 2022 | |
| 来源: Sage Journals | |
PDF
|
|
【 摘 要 】
Background:For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cemiplimab demonstrated significantly improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced NSCLC and PD-L1 ⩾50%. A systematic literature review and network meta-analysis (NMA) was conducted to identify/compare the efficacy/safety of cemiplimab versus pembrolizumab or other immune-oncology monotherapies from randomized-controlled trials (RCTs) published from January 2010 to November 2020.Methods:Relevant RCTs were identified by searching databases and conference proceedings as per ISPOR, NICE, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. NMA with time-varying hazard ratios (HRs) was performed for OS and PFS. Analyses were conducted for objective response rate (ORR) and safety/tolerability. Fixed-effect models were used due to limited evidence. Various sensitivity analyses were conducted to validate the base case analyses.Results:The feasibility assessment determined that EMPOWER-Lung 1, KEYNOTE-024, and KEYNOTE-042 trials were eligible. IMpower110 was excluded because an incompatible PD-L1 assay (SP142) was used for patient selection. For first-line advanced NSCLC with PD-L1 ⩾50%, cemiplimab was associated with statistically significant improvements in PFS [HR (95% credible interval [CrI]): 0.65 (0.50–0.86), 1–12 months] and ORR [odds ratio (OR) (95% CrI): 1.64 (1.04–2.62)], and comparable OS [HR (95% CrI): 0.77 (0.54–1.10), 1–12 months] versus pembrolizumab. There was no evidence of differences between cemiplimab and pembrolizumab for Grade 3–5 adverse events (AEs) [OR (95% CrI): 1.47 (0.83–2.60)], immune-mediated AEs [1.75 (0.33–7.49)], and all-cause discontinuation due to AEs [1.21 (0.58–2.61)].Conclusions:Considering the limitations of indirect treatment comparisons, in patients with advanced NSCLC and PD-L1 ⩾50%, cemiplimab monotherapy demonstrated significant improvements in PFS and ORR, comparable OS, and no evidence of differences in safety/tolerability versus pembrolizumab.
【 授权许可】
CC BY
© The Author(s), 2022
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202609140011611ZK.pdf | 762KB | ||
| RO202609140000501ZK.pdf | 7541KB | ||
| Figure 9 | 45KB | Image | |
| Figure 13 | 56KB | Image | |
| Figure 2 | 95KB | Image | |
| Figure 14 | 24KB | Image |
【 图 表 】
Figure 14
Figure 2
Figure 13
Figure 9
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]
- [57]
- [58]
- [59]
- [60]
- [61]
- [62]
- [63]
- [64]
- [65]
- [66]
- [67]
- [68]
- [69]
- [70]
- [71]
- [72]
- [73]
- [74]
- [75]
- [76]
- [77]
- [78]
- [79]
- [80]
- [81]
- [82]
- [83]
- [84]
- [85]
PDF